Sign in
Not yet taking people in United StatesPhase 2

Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis

Key facts

Who runs it
Lowell Anthony, MD
Where
Lexington, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
12 people, planned
Starts
16 Dec 2026
Expected to end
1 Jul 2029
Type of study
Interventional
Treatments tested
  • Everolimus
  • Bland Hepatic Artery Embolization
Record updated
18 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (29)Hide the full registry criteria

Who can take part

  • Patients must have histologically or cytologically confirmed Grade 1 or 2 NET with measurable liver metastasis (≥1.0 cm)
  • Morphologically progressive disease by RECIST 1.1 and/or ≥25% but ≤75% tumor burden in the liver
  • Prior tolerance of at least 5 mg daily everolimus for ≥5 days pre-HAE. NOTE: There is no maximum amount of time a patient may be taking Everolimus before HAE as the study focuses on after the pre-HAE dose is established
  • Prior therapy: Patients are eligible regardless of the number or type of prior therapies and without a requirement to have received a specific therapy prior to enrollment. Patients will take everolimus leading up to the embolization once enrolled in the study. They will only be enrolled in the study for their first hepatic artery embolization. They must be 30 days out since their last cancer treatment of any kind, not including somatostatin analogs
  • Age ≥18 years
  • ECOG performance status ≤2 (see Appendix A)
  • Patients must have adequate organ and marrow function as defined below:
  • absolute neutrophil count ≥1,000/mcL
  • platelets ≥100,000/mcL
  • total bilirubin ≤ institutional upper limit of normal (ULN)
  • Child-Turcotte-Pugh class A; B dose reduction is recommended at 5mg QD or less; C recommend non-usage of everolimus
  • Creatinine (or GFR) ≤ institutional ULN (Appendix B)
  • GFR, glomerular filtration rate (or creatinine) There are no dose reductions required for patients in any stage of renal failure for everolimus
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

Who cannot take part

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia
  • Prior transhepatic artery embolization
  • Prior chemotherapy or peptide receptor radionuclide therapy within 1 month
  • Patients who are receiving any other investigational agents for the treatment of this cancer
  • Concomitant medications: Patients should only be excluded from trial participation when clinically relevant known or predicted drug-drug interactions or potential overlapping toxicities will impact safety or efficacy. Drug-drug interactions of risk level X will be excluded from the trial unless an alternative medication can be substituted. Drug-drug interactions are classified into classes A, B, C, D and X. A Class X drug interaction represents a high-risk, contraindicated combination where the risks of taking the medications together clearly outweigh any potential benefits. These medications include Antihepaciviral Combination Products, BCG Products, Brivudine, Chikungunya Vaccine (Live), Chloramphenicol (Systemic), Cladribine, Dengue Tetravalent Vaccine (Live), Etrasimod, Fexinidazole, Grapefruit Juice, Inhibitors of CYP3A4 (Strong) and P-glycoprotein, Mumps- Rubella- or Varicella-Containing Live Vaccines, Nadofaragene Firadenovec, Natalizumab, Pimecrolimus, Pimozide, Poliovirus Vaccines (Live/Oral), Tacrolimus (Topical), Talimogene Laherparepvec, Tertomotide, Thiamphenicol, Typhoid Vaccine, Vaccines (Live), Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated). Additionally, patients should avoid taking everolimus while on strong CYP3A4 inhibitors. They should have everolimus dose reduction to 2.5 mg PO while on moderate CYP34A inhibitors and/or PgP inhibitors. An increase in everolimus dose is recommended when co-administered with a strong CYP3A4 inducer (see package insert, Appendix C)
  • Pregnant women are excluded from this study because everolimus is an mTOR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with everolimus, breastfeeding should be discontinued if the mother is treated with everolimus. NOTE: Patients treated with everolimus should use highly effective birth control during treatment and for 8 weeks after their last everolimus dosing. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with everolimus and for 4 weeks after the last dose
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to everolimus
  • Patients with uncontrolled intercurrent illness
  • Contraindication to arteriography or embolization
  • Biliary stent or choledocho-enteric anastomosis

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Neuroendocrine tumors or liver metastases

Where in United States

  • University of KentuckyLexington, United StatesContact: Lowell B Anthony, MDNot yet recruiting

About the trial

What the trial wants to find out

This study is being done to learn whether people with neuroendocrine tumors (NETs) that have spread to the liver can safely tolerate a lower dose of everolimus after bland hepatic artery embolization (HAE).

The group in the trial

  • Everolimus following Bland Hepatic Artery EmbolizationTreatment being tested

    Everolimus 5mg will be provided orally for 7 days pre embolization then every other day beginning day 2 through day 30, post embolization. Bland Hepatic Artery procedure will occur on Day 0.

    Treatment: Everolimus and Bland Hepatic Artery Embolization

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Dose Optimization Trial of Everolimus Post-Bland Hepatic Artery Embolization (Evero-Embo) in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis
Criteria questions
Built from NCT07946627, who can take part
Record updated
18 November 2026